Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Gordon L. Bray

Phase I Study of CC-486 Alone and in Combination With Carboplatin or Nab‑paclitaxel in Patients With Relapsed or Refractory Solid Tumors

Clinical Cancer Research

Cancer Research

Oncology

2018

English

Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance.

Molecular Cancer Research

English

Related publications

Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors

Clinical Cancer Research

Cancer Research

Oncology

2006

English

Phase I Study of 17-Allylamino-17 Demethoxygeldanamycin, Gemcitabine and/or Cisplatin in Patients With Refractory Solid Tumors

Investigational New Drugs

Oncology

Pharmacology

2010

English

Phase Ib Study of Cc-122 in Combination With Obinutuzumab (Ga101): Relapsed or Refractory (R/R) Patients With B-Cell Non-Hodgkin Lymphomas (Nhl)

Hematological Oncology

English

A Phase I Dose-Escalation Study of Selumetinib in Combination With Docetaxel or Dacarbazine in Patients With Advanced Solid Tumors

English

A Multi-Center Phase I Study of Clofarabine, Etoposide and Cyclophosphamide in Combination in Pediatric Patients With Refractory or Relapsed Acute Leukemia

English

Erratum To: A Phase I Dose-Escalation Study of Selumetinib in Combination With Erlotinib or Temsirolimus in Patients With Advanced Solid Tumors

Investigational New Drugs

Oncology

Pharmacology

2017

English

P1.16-21 Phase I / II Study of Carboplatin, Nab-Paclitaxel, and Concurrent Radiotherapy for Patients With Locally Advanced NSCLC

Journal of Thoracic Oncology

English

A Phase I Trial of Dasatinib, an SRC-Family Kinase Inhibitor, in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Recurrent Ovarian Cancer

Clinical Cancer Research

Cancer Research

Oncology

2012

English

Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Gordon L. Bray

Phase I Study of CC-486 Alone and in Combination With Carboplatin or Nab‑paclitaxel in Patients With Relapsed or Refractory Solid Tumors

Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance.

Related publications

Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors

Phase I Study of 17-Allylamino-17 Demethoxygeldanamycin, Gemcitabine and/or Cisplatin in Patients With Refractory Solid Tumors

Phase Ib Study of Cc-122 in Combination With Obinutuzumab (Ga101): Relapsed or Refractory (R/R) Patients With B-Cell Non-Hodgkin Lymphomas (Nhl)

A Phase I Dose-Escalation Study of Selumetinib in Combination With Docetaxel or Dacarbazine in Patients With Advanced Solid Tumors

A Multi-Center Phase I Study of Clofarabine, Etoposide and Cyclophosphamide in Combination in Pediatric Patients With Refractory or Relapsed Acute Leukemia

Erratum To: A Phase I Dose-Escalation Study of Selumetinib in Combination With Erlotinib or Temsirolimus in Patients With Advanced Solid Tumors

P1.16-21 Phase I / II Study of Carboplatin, Nab-Paclitaxel, and Concurrent Radiotherapy for Patients With Locally Advanced NSCLC

A Phase I Trial of Dasatinib, an SRC-Family Kinase Inhibitor, in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Recurrent Ovarian Cancer

Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma